PCSK9抑制剂治疗的患者可及性:事前授权与自付费用的关联
该研究基于2015年8月至2016年7月美国药房交易数据,纳入45 029例新开具PCSK9抑制剂处方的患者。仅47.2%的处方曾获批准,获批后65.3%被取药,最终仅30.9%的患者实际接受治疗;自付费用与处方弃用强烈相关,弃用率从0美元共付的7.5%升至超过350美元的75%以上。
要点
- 新开具PCSK9抑制剂处方的患者中,仅30.9%最终接受治疗。
- 政府保险较商业保险的获批概率更高(OR 3.3,95%CI 2.8-3.8)。
- 自付费用是处方弃用的最强预测因素(C统计量0.86)。
核心结论
- 在PCSK9抑制剂上市第一年,仅约半数处方获得批准,获批处方中约三分之一因共付费用未被取药。
研究设计与样本
- 基于美国药房交易数据的回顾性队列研究,纳入2015年8月1日至2016年7月31日新开具PCSK9抑制剂处方的45 029例患者。
主要发现
- 20.8%的患者在第一天获得批准,47.2%曾获得批准;获批者中65.3%取药,最终30.9%的患者接受治疗。
- 高龄、男性、合并动脉粥样硬化性心血管疾病者更易获批,但获批率不随低密度脂蛋白胆固醇水平或他汀使用而变化。
- 政府保险较商业保险获批的OR为3.3(95%CI 2.8-3.8),专业药房较零售药房取药的OR为1.96(95%CI 1.66-2.33)。
- 前10大药房福利管理机构的获批率差异近3倍。
- 处方弃用与共付费用最相关(C统计量0.86),弃用率从0美元共付的7.5%升至超过350美元的75%以上。
临床怎么用
- 处方PCSK9抑制剂时应评估患者保险类型与共付费用,提前告知批准与取药障碍。
- 对高共付费用患者可考虑协助寻求费用支持或选择专业药房以提高取药率。
局限性
- 研究仅基于药房交易数据,可能未涵盖所有临床变量与患者结局。
- 数据限于2015-2016年美国市场,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING, AND PARTICIPANTS: Using pharmacy transaction data, we evaluated 45 029 patients who were newly prescribed PCSK9i in the United States between August 1, 2015, and July 31, 2016. MAIN OUTCOMES AND MEASURES: The proportion of PCSK9i prescriptions approved and abandoned (approved but unfilled); multivariable analyses examined factors associated with approval/abandonment including payor, prescriber specialty, pharmacy benefit manager, out-of-pocket cost (copay), clinical diagnoses, lipid-lowering medication use, and low-density lipoprotein cholesterol levels. RESULTS: Of patients given an incident PCSK9i prescription, 51.2% were women, 56.6% were 65 years or older, and 52.5% had governmental insurance. Of the patients given a prescription, 20.8% received approval on the first day, and 47.2% ever received approval. Of those approved, 65.3% filled the prescription, resulting in 30.9% of those prescribed PCSK9i ever receiving therapy. After adjustment, patients who were older, male, and had atherosclerotic cardiovascular disease were more likely to be approved, but approval rates did not vary by patient low-density lipoprotein cholesterol level nor statin use. Other factors associated with drug approval included having government vs commercial insurance (odds ratio [OR], 3.3; 95% CI, 2.8-3.8), and those filled at a specialty vs retail pharmacy (OR, 1.96; 95% CI, 1.66-2.33). Approval rates varied nearly 3-fold among the top 10 largest pharmacy benefit managers. Prescription abandonment by patients was most associated with copay costs (C statistic, 0.86); with abandonment rates ranging from 7.5% for those with $0 copay to more than 75% for copays greater than $350. CONCLUSIONS AND RELEVANCE: In the first year of availability, only half of patients prescribed a PCSK9i received approval, and one-third of approved prescriptions were never filled owing to copay.
引用
- Navar AM, Taylor B, Mulder H, et al. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. JAMA Cardiol. 2017. PMID: 28973087. doi:10.1001/jamacardio.2017.3451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。